Cancer
Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Published in Cancer Weekly, November 27th, 2007
Genta Incorporated (NASDAQ:GNTA) released findings from the initial clinical dosing of G4544, the Company's proprietary small molecule that is intended as a treatment for diseases associated with accelerated bone loss. The Phase 1 study, which was conducted in normal volunteers, has shown good tolerance with oral bioavailability of the active ingredient, and an excellent safety profile without serious adverse reactions. The findings were released in an abstract published in the proceedings of the upcoming annual meeting of the American Society of Hematology.
G4544 is a new tablet formulation using delivery technology developed by Emisphere Technologies, Inc. that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-11-27)
More Articles from Cancer Weekly
- Cancer Vaccines
UGA researchers 1 step closer to elusive cancer vaccine - Breast Cancer
Preclinical Data Published in Cancer Science Show AVEO's Novel Oral EGFR Inhibitor AV-412 Effective in Drug-Resistant Cancers - Cancer Gene Therapy
Investigators at University of Navarra publish new data on cancer gene therapy - Cancer Gene Therapy
New cancer gene therapy study findings have been published by scientists at University of Alabama - Cancer Vaccines
Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia - Cancer Vaccines
Findings from University of California advance knowledge in cancer vaccines - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
